印度仿制型制药企业的转型升级路径研究及其对我国的启示——以雷迪博士为例

Research on the transformation and upgrading pathway of Indian pharmaceutical companies and its enlightenment to China——an empirical study on Dr Reddy's Labs

摘要:

印度是以原料药和仿制药为核心优势的制药强国,医药产业在发展过程中也培育出了很多具有国际影响力的制药企业,成为发展中国家医药产业升级的典范。本文以印度第二大制药企业雷迪博士实验室公司为研究对象,通过研究其“大宗原料药—特色原料药—仿制药—创新药”的转型升级路径,总结雷迪博士在转型过程中的经验和策略。最终,结合我国实际情况,针对企业转型的不同阶段提出合理化建议,以期为提高我国仿制药质量、促进我国仿制药企业的转型升级提供经验借鉴。

Abstract:

India, which is a powerful nation in pharmaceutical industry, possesses ingredients and generic drugs as core competence. Many pharmaceutical companies with great international influence was cultivated in the process. As a result, India can become the model for developing country. In this paper, Dr Reddy"s Laboratories, the second biggest pharmaceutical companies in India, was taken as the object of study. The pathway of transformation and upgrading of Dr Reddy"s Labs, including key link such as Common API, characteristic API, generic drug and novel drug was studied, so as to summarize the strategy and experience of transformation and upgrading. Ultimately, combining our actual condition, to provide a reference for improving the quality of generic drugs, as well as promoting transformation and upgrading of pharmaceutical industry is essential and necessary.